A1C is a measure of blood sugar over a period of time, rather than an instantaneous reading, and shows more steady results
ECC5004 further strengthens our existing pipeline addressing both incretin and non-incretin pathways, including our GLP-1/glucagon dual agonist [AZD9550] and long-acting amylin analogue [AZD6234]. Preliminary results from a Phase I trial in the United States suggest ECC5004 has a different profile from most of the current drugs, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo
GLP-1 Based Therapeutic Summit Schedule: May 15, 2024 - May 16, 2024 Location: Hilton Philadelphia City Avenue, Philadelphia, 19131 About the Event Amidst the resounding success of Novos SELECT trial, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments
Other bias was assessed from single-centre versus multi-centre study, study size compared to other study of nutrition, and the influence from funders